FIELD: pharmacology.
SUBSTANCE: invention relates to compounds of the general formula
, their pharmaceutically acceptable salts, pharmaceutical compositions containing the said compounds.
EFFECT: compounds of general formula I are XIa factor inhibitors and are suitable for thromboembolic diseases prevention or treatment.
22 cl, 1 tbl, 115 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBACTERIAL AGENT | 2000 |
|
RU2269525C2 |
DERIVATIVES OF DIAMINES | 2002 |
|
RU2319699C2 |
QUINOLINE-2 DERIVATIVES AS C-KIT KINASE INHIBITORS | 2016 |
|
RU2754858C2 |
DIPEPTIDYL PEPTIDASE-IV INHIBITORS | 2010 |
|
RU2574410C2 |
DERIVATIVES OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES AND RESPIRATORY WAYS DISEASES | 2001 |
|
RU2265011C2 |
DIAMINE DERIVATIVES | 2002 |
|
RU2314303C2 |
MELANOCORTIN RECEPTOR AGONISTS | 2007 |
|
RU2411240C2 |
APOPTOSIS-INDUCING MEANS FOR TREATMENT OF MALIGNANT TUMOUR AND IMMUNE AND AUTOIMMUNE DISEASES | 2015 |
|
RU2628885C2 |
APOPTOSIS INDUCING AGENTS FOR TREATING MALIGNANT NEW GROWTH, AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2535347C2 |
AMINOPYRIMIDINE DERIVATIVES AND USE THEREOF AS AROMATIC HYDROCARBON RECEPTOR MODULATORS | 2021 |
|
RU2826628C1 |
Authors
Dates
2017-11-20—Published
2013-05-23—Filed